121 related articles for article (PubMed ID: 33381320)
1. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer.
Samar A; Tiwari S; Subramanian S; Joshi N; Sejpal J; Khan MA; Ahmad I
Prostate Cancer; 2020; 2020():4242989. PubMed ID: 33381320
[TBL] [Abstract][Full Text] [Related]
2. Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series.
Tiwari S; Bisaria A; Kaur H; Joshi N; Sejpal J; Khan MA
J Oncol Pharm Pract; 2021 Dec; 27(8):2030-2034. PubMed ID: 33853469
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study.
Narayanan P; Dattatreya PS; Prasanna R; Subramanian S; Jain K; Somanath NS; Joshi N; Bunger D; Khan MA; Chaturvedi A; Ahmad I
Sarcoma; 2019; 2019():3158590. PubMed ID: 31827370
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.
Subramanian S; Majumdar SKD; Biswas G; Joshi N; Bunger D; Khan MA; Ahmad I
Mol Clin Oncol; 2020 Sep; 13(3):14. PubMed ID: 32754328
[TBL] [Abstract][Full Text] [Related]
5. Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study.
Subramanian S; Prasanna R; Biswas G; Das Majumdar SK; Joshi N; Bunger D; Khan MA; Ahmad I
Breast Cancer (Dove Med Press); 2020; 12():77-85. PubMed ID: 32547188
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study.
Subramanian S; Samar A; Joshi N; Sejpal J; Khan MA; Ahmad I
Mol Clin Oncol; 2021 Aug; 15(2):162. PubMed ID: 34194740
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study.
Kumar Das Majumdar S; Subramanian S; Biswas G; Joshi N; Khan MA; Ahmad I
Oncol Lett; 2020 Dec; 20(6):344. PubMed ID: 33123255
[TBL] [Abstract][Full Text] [Related]
8. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer.
Badiginchala R; Dattatreya PS; Suresh AVS; Nirni SS; Andra VV; Bunger D; Chaturvedi A
Onco Targets Ther; 2023; 16():215-225. PubMed ID: 37033671
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
12. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
13. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M; Carducci MA; Slovin S; Cetnar J; Qian J; McKeegan EM; Refici-Buhr M; Chyla B; Shepherd SP; Giranda VL; Alumkal JJ
Invest New Drugs; 2014 Oct; 32(5):904-12. PubMed ID: 24764124
[TBL] [Abstract][Full Text] [Related]
16. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Barroso-Sousa R; da Fonseca LG; Souza KT; Chaves AC; Kann AG; de Castro G; Dzik C
Med Oncol; 2015 Jan; 32(1):443. PubMed ID: 25519824
[TBL] [Abstract][Full Text] [Related]
17. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.
Byeon S; Kim H; Kim J; Kwon M; Hur JY; Jeon HG; Jeon SS; Lee HM; Park SH
Investig Clin Urol; 2020 Nov; 61(6):588-593. PubMed ID: 32985144
[TBL] [Abstract][Full Text] [Related]
19. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
20. Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
Bejrananda T; Pripatnanont C; Tanthanuch M; Karnjanawanichkul W
J Med Assoc Thai; 2016 Dec; 99(12):1315-21. PubMed ID: 29952517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
